Shanghai Fosun Pharmaceutical Stock Current Valuation
SFOSF Stock | USD 1.67 0.04 2.34% |
Valuation analysis of Shanghai Fosun Pharm helps investors to measure Shanghai Fosun's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Overvalued
Today
Please note that Shanghai Fosun's price fluctuation is dangerous at this time. Calculation of the real value of Shanghai Fosun Pharm is based on 3 months time horizon. Increasing Shanghai Fosun's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Our valuation method for Shanghai Fosun Pharmaceutical is useful when determining the fair value of the Shanghai pink sheet, which is usually determined by what a typical buyer is willing to pay for full or partial control of Shanghai Fosun. Since Shanghai Fosun is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Shanghai Pink Sheet. However, Shanghai Fosun's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. Historical | Market 1.67 | Real 1.49 | Hype 1.67 | Naive 1.58 |
The real value of Shanghai Pink Sheet, also known as its intrinsic value, is the underlying worth of Shanghai Fosun Pharm Company, which is reflected in its stock price. It is based on Shanghai Fosun's financial performance, assets, liabilities, growth prospects, management team, or industry conditions. The intrinsic value of Shanghai Fosun's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Shanghai Fosun's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Shanghai Fosun Pharmaceutical helps investors to forecast how Shanghai pink sheet's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Shanghai Fosun more accurately as focusing exclusively on Shanghai Fosun's fundamentals will not take into account other important factors: Shanghai Current Valuation Analysis
Shanghai Fosun's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Shanghai Fosun Current Valuation | 15.52 B |
Most of Shanghai Fosun's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Shanghai Fosun Pharmaceutical is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Competition |
In accordance with the recently published financial statements, Shanghai Fosun Pharmaceutical has a Current Valuation of 15.52 B. This is 8.02% higher than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The current valuation for all United States stocks is 6.67% higher than that of the company.
Shanghai Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Shanghai Fosun's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Shanghai Fosun could also be used in its relative valuation, which is a method of valuing Shanghai Fosun by comparing valuation metrics of similar companies.Shanghai Fosun is currently under evaluation in current valuation category among related companies.
Shanghai Fundamentals
Return On Equity | 0.0756 | |||
Return On Asset | 0.0204 | |||
Profit Margin | 0.08 % | |||
Operating Margin | 0.07 % | |||
Current Valuation | 15.52 B | |||
Shares Outstanding | 551.94 M | |||
Shares Owned By Insiders | 0.07 % | |||
Shares Owned By Institutions | 35.60 % | |||
Price To Earning | 13.80 X | |||
Price To Book | 1.45 X | |||
Price To Sales | 0.31 X | |||
Revenue | 39.01 B | |||
Gross Profit | 18.71 B | |||
EBITDA | 8.71 B | |||
Net Income | 4.74 B | |||
Cash And Equivalents | 14.64 B | |||
Cash Per Share | 5.49 X | |||
Total Debt | 9.05 B | |||
Debt To Equity | 0.64 % | |||
Current Ratio | 1.00 X | |||
Book Value Per Share | 16.30 X | |||
Cash Flow From Operations | 3.95 B | |||
Earnings Per Share | 0.21 X | |||
Number Of Employees | 36.28 K | |||
Beta | 0.76 | |||
Market Capitalization | 12.25 B | |||
Total Asset | 93.29 B | |||
Retained Earnings | 10.37 B | |||
Working Capital | (817 M) | |||
Current Asset | 10.27 B | |||
Current Liabilities | 11.09 B | |||
Z Score | 0.6 | |||
Annual Yield | 0.03 % | |||
Net Asset | 93.29 B | |||
Last Dividend Paid | 0.56 |
About Shanghai Fosun Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Shanghai Fosun Pharmaceutical's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Shanghai Fosun using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Shanghai Fosun Pharmaceutical based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Shanghai Fosun Pharmaceutical Co., Ltd. develops, manufactures, and sells pharmaceutical products in Mainland China and internationally. Shanghai Fosun Pharmaceutical Co., Ltd. was founded in 1994 and is based in Shanghai, China. Shanghai Fosun operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. It employs 36604 people.
Currently Active Assets on Macroaxis
Check out Shanghai Fosun Piotroski F Score and Shanghai Fosun Altman Z Score analysis. You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
Complementary Tools for Shanghai Pink Sheet analysis
When running Shanghai Fosun's price analysis, check to measure Shanghai Fosun's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Shanghai Fosun is operating at the current time. Most of Shanghai Fosun's value examination focuses on studying past and present price action to predict the probability of Shanghai Fosun's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Shanghai Fosun's price. Additionally, you may evaluate how the addition of Shanghai Fosun to your portfolios can decrease your overall portfolio volatility.
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
Stocks Directory Find actively traded stocks across global markets | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like |